$16.08-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $730M to $760M for Fiscal year 2026 — up 10.7% on a year earlier
Just reported
From Ultragenyx Pharmaceutical Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$173M
+8.1% y/y
-19% q/q
Guided
—
No guide given
Actual
-$1.16
Guided
—
No guide given
Actual
-$110M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $173M | $160M | +8.13% |
| Profit | -$118M | -$180M | +34.44% |
| Profit per share | -$1.16 | -$1.81 | +35.91% |
| Free Cash Flow | -$45M | -$92M | +51.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Ultragenyx Pharmaceutical Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ultragenyx Pharmaceutical Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.